Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 4/20 | 0.53 |
| ▸ | ESR1 | P03372 | 12/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69907 | 0.79 | GAA (0.58) | RAPGEF4ESR1ESR2GAAALDH1A1 | |
| SCHEMBL29599083 | 0.79 | GAA (0.58) | RAPGEF4ESR1ESR2GAAALDH1A1 | |
| SCHEMBL8493545 | 0.76 | GAA (0.60) | RAPGEF4ESR1ESR2GAAALDH1A1 | |
| SCHEMBL8908176 | 0.76 | GAA (0.60) | RAPGEF4ESR1ESR2GAAALDH1A1 | |
| SCHEMBL12084146 | 0.74 | ALDH1A1 (0.67) | ESR1GAAALDH1A1PKMMAPT | |
| SCHEMBL30676220 | 0.73 | ESR1 (0.71) | ESR1ESR2GAAALDH1A1AR | |
| SCHEMBL1416648 | 0.73 | ESR1 (0.71) | ESR1ESR2GAAALDH1A1AR | |
| SCHEMBL12460963 | 0.73 | GAA (0.61) | RAPGEF4GAAALDH1A1PKMCA2 | |
| SCHEMBL9600349 | 0.72 | ESR1 (0.43) | RAPGEF4ESR1GAAALDH1A1PKM | |
| SCHEMBL9460744 | 0.71 | POLB (0.59) | ESR1ESR2GAAALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829552-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | PYGL, THRA, THOP1 | RAPGEF4 3538/4885ESR1 1256/4885ESR2 2127/4885 |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | THRA, PYGL, THRB | RAPGEF4 3282/4885ESR1 1422/4885ESR2 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.